Prothena Announces Proposed Offering of Ordinary Shares
06 avr. 2015 16h01 HE
|
Prothena Corporation plc
DUBLIN, Ireland, April 6, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena Reports Robust Reduction of Free Serum Alpha-Synuclein of up to 96% After Single Dose of PRX002, a Novel Protein Immunotherapy for Parkinson's Disease
19 mars 2015 16h05 HE
|
Prothena Corporation plc
All Doses of PRX002 Found to be Safe and Well Tolerated, Meeting Primary Objective of Phase 1 Single Ascending Dose Study
Results of Study Demonstrate Rapid and Dose-Dependent Reduction of...
Prothena Reports Fourth Quarter and Full Year 2014 Financial Results and Provides 2015 Financial Guidance and R&D Update
05 mars 2015 16h05 HE
|
Prothena Corporation plc
Net cash used in operating activities was $12.5 million in the fourth quarter and $0.7 million for the full year of 2014; year-end cash position of $293.6 million provides solid runway for...
Prothena to Report Fourth Quarter and Full Year 2014 Financial Results and Host Webcast and Conference Call on March 5
19 févr. 2015 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Feb. 19, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena to Present at the 2015 RBC Capital Markets' Healthcare Conference in New York on February 25
18 févr. 2015 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Feb. 18, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena Receives FDA Fast Track Designation for NEOD001, a Monoclonal Antibody for the Treatment of Patients With AL Amyloidosis
15 déc. 2014 16h05 HE
|
Prothena Corporation plc
First Investigational Immunotherapy for AL Amyloidosis to Receive FDA Fast Track Designation
Follows Recent Initiation of The VITAL Amyloidosis Study, a Global Phase 3 Registrational Trial of...
Prothena to Present at the Oppenheimer 25th Annual Healthcare Conference in New York
08 déc. 2014 16h05 HE
|
Prothena Corporation plc
DUBLIN, Dec. 8, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel...
Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis
02 déc. 2014 16h05 HE
|
Prothena Corporation plc
New and Updated Results Show 50% Response Rate in 14 Cardiac-Evaluable Patients
New Data Show 43% Best Response Rate in 14 Renal-Evaluable Patients
Cardiac and Renal Biomarker...
Prothena Reports Third Quarter 2014 Financial Results and R&D Progress
03 nov. 2014 16h05 HE
|
Prothena Corporation plc
Net cash used in operating activities was $12.3 million in the third quarter, while quarter-end cash position of $306.2 million provides solid runway for advancement of multiple programs...
Prothena Announces Presentation at Federation of European Physiological Societies 2014 Congress
26 août 2014 16h05 HE
|
Prothena Corporation plc
Data to be Presented by Dr. Timo Siepmann on the Discovery of a Potential New Non-Invasive Biomarker for Parkinson's Disease
Results Extend Prior Research Confirming Skin Response (Goose...